Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raltegravir once-daily reformulation versus twice-daily raltegravir with Truvada in treatment-naive HIV-1 infection
2013-001939-47Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of raltegravir and emtricitabine + tenofovir disoproxil in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Merck & Co. Primary endpoint: Proportion of subjects achieving HIV-1 RNA <40 copies/mL at Week 48. Started Feb 2014; status: completed.
02
Drugs
raltegraviremtricitabine + tenofovir disoproxil
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2013-001939-47.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001939-47.